- Quality of life patient-reported outcomes: QLQ30 and PR25- Physician-reported CTCAE Genitourinary (GU) and Gastrointestinal (GI) late toxicity- PSA (Prostate Specific Antigen) biochemical failure- Distant metastatic failure- Overall and prostate cancer specific survival. This evidence concerns the gene KLK3 and prostate cancer.